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1 |  INTRODUCTION
We describe a patient with gynecomastia and pseudohyperal-
dosteronism caused by posaconazole treatment of pulmonary 
coccidioidomycosis infection. Gynecomastia has not previ-
ously been reported in posaconazole therapy. Substitution of 
posaconazole by voriconazole reversed blood pressure and 
serum potassium while gynecomastia remained unchanged. 
Early detection by endocrine measurements may help pre-
venting gynecomastia.
Adverse drug effects account for up to 20% of all cases 
of gynecomastia.1 Drugs can disrupt hormonal regulation, 
thereby affecting ductal growth, alveolar differentiation, 
and subcutaneous fat deposition, which can contribute 
to male breast development. In particular, an increase in 
estradiol and progesterone levels with a concomitant de-
crease in testosterones can lead to gynecomastia. Drugs 
enhancing estrogen action promote ductal growth, med-
ications increasing progesterone and prolactin levels can 
influence alveolar differentiation, and substances reduc-
ing androgen levels decrease their inhibitory effects on 
breast development and result in relatively increased ef-
fects of breast-promoting hormones, thereby resulting in 
male breast development. Other hormones such as growth 
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Abstract
Posaconazole therapy may lead to increased serum estradiol levels and development 
of gynecomastia. Early detection by endocrine hormone measurements may help 
preventing gynecomastia.
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hormone (GH), insulin-like growth factor (IGF-1), prolac-
tin, cortisol, and thyroid hormone act as permissive trophic 
factors and require an imbalance of estrogens and andro-
gens for the development of gynecomastia. The sex steroids 
estradiol and progesterone require other mediators (eg, GH 
and IGF-1) to sustain breast development.
The currently available azole antifungal agents used 
for systemic treatment are not fully selective, and besides 
blocking fungal ergosterol synthesis by inhibiting lanosterol 
14α-demethylase (CYP51), they can cause adverse effects 
by interfering with human steroidogenic cytochrome P450 
(CYP) enzymes. This can lead to adverse drug-drug and 
drug-hormone interactions. The best-studied example is the 
imidazole-based antifungal compound ketoconazole, well 
known to cause gynecomastia, with an incidence of 4%-8% at 
lower doses (200-400 mg/day) and up to about 21% at higher 
doses (800-1200 mg/day).2-4 These effects may be most fre-
quent with long-term therapy, subjecting patients to prolonged 
elevation of the estradiol/testosterone ratio. Ketoconazole has 
been found to markedly decrease serum testosterone concen-
trations, with a much smaller effect on estradiol, thereby sig-
nificantly increasing the estradiol/testosterone ratio.5
Ketoconazole may alter estradiol and testosterone levels 
through multiple mechanisms. It was found to inhibit the 
adrenal 11β-hydroxylase (CYP11B1), increasing the 11-de-
oxycortisol/cortisol ratio by 15- to 80-fold.6 Inhibition of 
this critical enzymatic step was found in some cases to be 
associated with gynecomastia, probably due to an enhanced 
adrenal androgen production because of inhibition of cortisol 
synthesis. Ketoconazole also inhibits 17α-hydroxylase and 
17,20-lyase (both key steps in testosterone synthesis cata-
lyzed by the same enzyme, ie, CYP17A1). As a result, less 
androgens are produced, and subsequently, also fewer estro-
gens are formed via aromatase (CYP19A1). Furthermore, 
ketoconazole can displace estradiol from sex hormone–bind-
ing globulin (SHBG),7 potentially resulting in increased es-
tradiol levels. Additionally, ketoconazole can block androgen 
receptor binding of testosterone and dihydrotestosterone, 
thereby decreasing androgen signaling and altering the an-
drogen-estrogen balance toward the latter.8 These numerous 
“off-target” effects relegated ketoconazole to the treatment 
of hypercortisolism and castration-resistant prostate cancer 
while newer triazole (nonimidazole) antifungals have re-
placed its use in the treatment of systemic fungal infections.
The newer triazole antifungals (fluconazole, itraconazole, 
voriconazole, posaconazole, and isavuconazole) have not 
been reported to cause similar endocrinologic manifestations, 
despite nearly 30 years of clinical experience with these tri-
azoles. A new formulation of posaconazole (delayed-release 
tablets) has recently become available with resultant in-
creases in serum drug concentrations compared to the pre-
viously prescribed oral solution formulation.9 This has been 
viewed as a favorable clinical development and has been a 
welcome addition to the antifungal armamentarium, given 
past studies finding improvements in posaconazole efficacy 
in the treatment of invasive fungal disease with higher serum 
drug concentrations.10 These higher levels, although poten-
tially optimizing the efficacy, have recently been observed 
to be associated with adverse endocrinologic effects, specifi-
cally the pseudohyperaldosteronism caused by the inhibition 
of CYP11B1 and/or 11β-hydroxysteroid dehydrogenase type 
2 (11β-HSD2).11-13 Although this adverse event has only re-
cently been recognized and less than 20 cases have thus far 
been reported in detail,14 gynecomastia had previously not 
been observed in association with posaconazole-induced 
pseudohyperaldosteronism.
2 |  CASE REPORT
A 38-year-old African American male with no prior past 
medical history was diagnosed with pulmonary coccidioi-
domycosis approximately 11 months prior to referral to the 
hospital. He initially had symptoms of fever, chills, chest 
pain, and weight loss, and was found to have a right lower 
lobe pneumonia and osteomyelitis of the right clavicle con-
sistent with disseminated coccidioidomycosis. Laboratory 
results returned and were unremarkable with the exception 
of a positive Coccidioides complement fixation titer of 1:32 
and a C-reactive protein level of 254 mg/L. He was placed 
on oral fluconazole 600 mg/day. Over the next 8 weeks, he 
developed xerosis, cheilitis, and alopecia and refused fur-
ther fluconazole therapy. He was subsequently transitioned 
to posaconazole delayed-release tablets 300 mg/d. At return 
visit 5 months later, he was symptom-free and the patient's 
coccidioidal complement fixation titer had decreased to 1:8. 
However, he had developed new onset of gynecomastia, sup-
ported by a mammogram showing benign fibrotic tissue, 
along with hypertension (blood pressure 155/98, heart rate 
51). The mammogram did, however, not reveal any tumor. 
The normal human chorionic gonadotropin (hCG), follicle-
stimulating hormone (FSH), luteinizing hormone (LH), 
testosterone, and prolactin levels (Table  1) suggested the 
absence of prolactinoma or Leydig or Sertoli cell, and ad-
renal hormone–producing tumors. Furthermore, the patient 
had no nausea, diarrhea, or vomiting, and he was on no other 
medication and denied the use of any steroid supplements 
and estrogen-rich foods.
The development of posaconazole-induced hyperten-
sion was further analyzed by laboratory testing (Table 1). 
As observed in previous cases,11,14,15 posaconazole-in-
duced hypertension was accompanied by hypokalemia and 
undetectably low aldosterone. In contrast to previous cases, 
renin was in the normal range, although at the lower end, 
and neither 11-deoxycortisol level nor the cortisol-to-cor-
tisone ratio was elevated. The other hormones, compared 
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to reference ranges,16,17 assessed were in the normal range, 
including testosterone; however, estradiol was significantly 
elevated.
Posaconazole therapy was then discontinued, and the pa-
tient was started on voriconazole 200  mg twice daily. The 
patient returned to clinic 4 months later, and at this time, his 
endocrinology laboratory values had normalized, with the 
exception of aldosterone that was now elevated at 31 ng/dL. 
However, his gynecomastia remained unchanged, although 
estradiol with 22 pg/mL was almost back to normal range. 
Since the discontinuation of posaconazole treatment, the pa-
tient is asymptomatic for almost 18 months now.
3 |  DISCUSSION
To our knowledge, this is the first case of posaconazole-induced 
gynecomastia. However, we have noted elevated serum estra-
diol levels, but without signs of gynecomastia, in a previous 
case,18 suggesting that this adverse effect might be underesti-
mated. Different mechanisms may explain the patient's elevated 
estradiol level. As a compensatory response to the inhibition 
of CYP11B1 by posaconazole, the adrenal steroidogenesis is 
enhanced and secreted adrenal androgens may be converted 
to estrogens in peripheral tissues. In this regard, CYP11B1 
deficiency has been recognized as a cause of prepubertal gy-
necomastia, and enhanced adrenal androgen production with 
subsequent peripheral aromatization of androstenedione and 
testosterone is most likely responsible for the feminizing 
characteristics, although mineralocorticoids may also be in-
volved.19,20 Interestingly, biochemical evidence suggests that 
posaconazole can inhibit CYP17A1, mainly the lyase reac-
tion,12,21 which is needed for generation of both androgens and 
estrogens. Nevertheless, testosterone was normal in our patient 
while estradiol was significantly elevated (Table 1).
Alternatively, posaconazole, like ketoconazole, may re-
sult in decreased hepatic degradation of estrogens due to 
the inhibition of CYP3A4 and CYP3A7. A decreased con-
version of estrone to 16α-hydroxyestrone and estradiol to 
estriol may lead to elevated estrogen levels and a disturbed 
estrogen to androgen balance. Furthermore, follow-on stud-
ies should also include enzymes involved in androgen and 
estrogen sulfation, and transporters of androgens and estro-
gens. Additionally, it remains unclear whether posaconazole 
decreases the binding of sex steroids to SHBG, leading to 
elevated free concentrations.
In contrast to previously described cases of posacon-
azole-induced pseudohyperaldosteronism (PIPH) showing 
either elevated 11-deoxycortisol, indicating CYP11B1 in-
hibition, or an increased cortisol to cortisone ratio, a bio-
marker of decreased 11β-HSD2 activity,11,14,15,22 this patient 
presented with 11-deoxycortisol and a cortisol to cortisone 
ratio in the normal range (Table 1). As previously seen, al-
dosterone was undetectable but renin was at the lower end of 
the normal range. The serum posaconazole level was some-
what lower than in most previously reported cases of PIPH 
showing >3 μg/mL. Thus, the concentration achieved in our 
patient may not have been high enough to inhibit CYP11B1 
and/or 11β-HSD2 sufficiently to cause feedback stimulation, 
resulting in elevated serum 11-deoxycortisol and/or cortisol 
to cortisone ratio. It needs to be noted that 24-hour urine, 
which yields more sensitive information on changes in steroid 
homeostasis, was not available. The failure to detect aldoste-
rone can be explained by the potent inhibition of aldosterone 
synthase (CYP11B2), which is more potently inhibited by 
posaconazole than CYP11B1.12,21 The exact mechanism of 
hypertension and hypokalemia in this patient remains un-
clear. Enhanced sensitivity of the mineralocorticoid receptor 
by enhanced intracellular availability of corticosteroids or 
post-translational modifications leading to enhanced receptor 
activation should be considered.
Nevertheless, substitution of posaconazole by 
voriconazole reversed the adverse effect on blood pressure, 
serum potassium, and endocrine hormones as seen in previ-
ous cases.11,14 The fact that gynecomastia still persisted after 
discontinuation of posaconazole treatment is not surprising. 
Even with a return to normal estrogen levels, gynecomastia in 
males is frequently permanent as the breast tissue undergoes 
fibrosis, as was seen in our case. This emphasizes the need 
for detecting disturbances of endocrine hormones as early as 
possible during posaconazole treatment.






Posaconazole level (µg/mL) 2.64
Renin (ng/mL/h) 0.6 0.25-5.82
Aldosterone (ng/dL) <1 2.0-18
11-Deoxycortisol (ng/dL) 40 <158
Serum potassium 3.3 3.5-5.0
Estradiol (pg/mL 63 <20
Cortisol (µg/dL) 11.1 5.0-25
Cortisone (µg/dL) 1.8 1.0-3.5
Cortisol/Cortisone 6.2 2-8
TSH (μU/mL) 0.80 0.5-4.7
T4 (free) (ng/dL) 1.1 0.8-2.7
Prolactin ng/mL 8.8 0-15
FSH (mIU/mL) 6.6 1.0-12.0
LH (mIU/mL) 7.8 2.0-12.0
Testosterone, total (ng/dL) 631 200-1070
HCG (mIU/mL) <2 <5
Values outside the normal range are shown in bold.
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In conclusion, we report the first case of posaconazole-in-
duced gynecomastia and review the known adrenal enzymatic 
pathways responsible for the development of drug-induced 
gynecomastia. Future work further delineating the exact 
pathophysiologic mechanism(s) behind posaconazole-in-
duced gynecomastia should be undertaken to more fully un-
derstand what might be an underreported phenomenon.
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